Patents by Inventor A. Richard Kennedy
A. Richard Kennedy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11933785Abstract: This invention provides minimally invasive methods, reagents, diagnostic and prognostic markers useful for staging, prognosis and surveillance of colorectal cancers, and therapeutic intervention in individuals with colorectal cancers, or individuals who may be susceptible to developing colorectal cancers.Type: GrantFiled: June 12, 2017Date of Patent: March 19, 2024Assignee: Wisconsin Alumni Research FoundationInventors: Michael Richard Sussman, Melanie Mae Ivancic, Gregory D Kennedy, William Franklin Dove, Perry Joseph Pickhardt, Mark Reichelderfer
-
Publication number: 20230019487Abstract: A cargo rack is usable to store electronic devices, such as servers, while the electronic devices operate. The cargo rack has a telescoping enclosure with one or two doors for selectively closing either or both ends of the enclosure. The cargo rack also includes an onboard electronic system. The electronic system includes a programmable controller and an access control system for selectively locking or unlocking the door or doors of the enclosure. The access control system includes a security interface at which access credentials may be presented from outside the enclosure for recognition by electronics within the enclosure.Type: ApplicationFiled: June 30, 2022Publication date: January 19, 2023Inventors: Zachariah Gregory Francis, Bodie William Francis, Devin Richard Kennedy, Nicola Andrew Foggi
-
Publication number: 20220265900Abstract: The invention relates to implantable systems for repairing and restoring cartilage. The invention provides methods and products for cartilage repair that use universal chondrocytes. A universal cell line includes cells such as universal chondrocytes that are not immunogenic or allergenic and can be grown in products suitable for use in a number of different people. Use of the universal chondrocytes allows for new processes and products. Where prior art autologous neocartilage constructs required many small reactors (e.g., at least one culture dish per patient to grow one 34 mm disc per patient), using a universal cell line allows, for example, one large batch of cartilage or neocartilage to be made under uniform conditions.Type: ApplicationFiled: February 10, 2022Publication date: August 25, 2022Applicant: Histogenics CorporationInventor: Stephen Richard KENNEDY
-
Patent number: 11254986Abstract: An immune response subtype of cancer is associated with DNA damage which allows subjects to be stratified for particular therapies including immune therapies which may be combined with DNA damage therapeutics. A method for predicting responsiveness to an antagonist of an inhibitory immune checkpoint and/or an agonist of a stimulatory immune checkpoint comprises determining the expression level of at least one gene selected from Table 2B, 2A or 1 in a sample from the subject. The determined expression level is used to predict responsiveness to an antagonist of an inhibitory immune checkpoint and/or an agonist of a stimulatory immune checkpoint.Type: GrantFiled: July 21, 2016Date of Patent: February 22, 2022Assignee: Almac Diagnostics Services LimitedInventors: Timothy Davison, Jude O'Donnell, Max Bylesjo, Fionnuala Patterson, Steve Deharo, Laura A. Hill, Katherine E. Keating, Vitali Proutski, Denis Paul Harkin, Richard Kennedy, Nicolas Goffard, Steven Walker, Laura Taggart, Eileen Parkes
-
Publication number: 20210254166Abstract: Methods for characterising and/or prognosing cancer in a subject comprise determining the expression level of at least one, and preferably 12, genes selected from Table 1 in a sample from the subject wherein the determined expression level is used to provide a characterisation of and/or a prognosis for the cancer. Determined expression levels are used to generate a signature score. The methods permit metastatic disease to be identified and monitored and guide therapeutic interventions.Type: ApplicationFiled: June 17, 2016Publication date: August 19, 2021Applicant: ALMAC DIAGNOSTICS LIMITEDInventors: Steven WALKER, Laura HILL, Andrena MCCAVIGAN, Sinead DONEGAN, Timothy DAVISON, Richard KENNEDY, Denis Paul HARKIN, Bethanie PRICE
-
Patent number: 11091809Abstract: Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test identifies cancer subtypes that have an up-regulation or a down-regulation in biomarker expression related to angiogenesis and vascular development. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any anti-angiogenic agent. This test may be used in different cancer types and with different drugs that directly or indirectly affect angiogenesis or angiogenesis signalling. In addition, the present invention may be used as a prognostic indicator for certain cancer types. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.Type: GrantFiled: December 3, 2013Date of Patent: August 17, 2021Assignee: Almac Diagnostic Services LimitedInventors: Denis Paul Harkin, Fionnuala Patterson, Claire Trinder, Eamonn J. O'Brien, Caroline Michie, Charlie Gourley, Laura A. Hill, Katherine E. Keating, Jude O'Donnell, Max Bylesjo, Steve Deharo, Vitali Proutski, Richard Kennedy, Timothy Davison, Andreas Winter, Andrena McCavigan
-
Patent number: 10738310Abstract: This present invention compositions and methods of treating cancer and methods of accessing/monitoring the responsiveness of a cancer cell to a therapeutic compound.Type: GrantFiled: November 23, 2015Date of Patent: August 11, 2020Assignee: Dana-Faber Cancer Institute, Inc.Inventors: Alan D'Andrea, David T. Weaver, Markus Grompe, Richard Kennedy
-
Publication number: 20200140868Abstract: This present invention compositions and methods of treating cancer and methods of accessing/monitoring the responsiveness of a cancer cell to a therapeutic compound.Type: ApplicationFiled: August 12, 2019Publication date: May 7, 2020Inventors: Alan D. D'ANDREA, David T. WEAVER, Markus GROMPE, Richard KENNEDY
-
Publication number: 20200086005Abstract: The invention relates to implantable systems for repairing and restoring cartilage. The invention provides methods and products for cartilage repair that use universal chondrocytes. A universal cell line includes cells such as universal chondrocytes that are not immunogenic or allergenic and can be grown in products suitable for use in a number of different people. Use of the universal chondrocytes allows for new processes and products. Where prior art autologous neocartilage constructs required many small reactors (e.g., at least one culture dish per patient to grow one 34 mm disc per patient), using a universal cell line allows, for example, one large batch of cartilage or neocartilage to be made under uniform conditions.Type: ApplicationFiled: April 25, 2019Publication date: March 19, 2020Applicant: HISTOGENICS CORPORATIONInventor: Stephen Richard Kennedy
-
Publication number: 20190316203Abstract: An immune response subtype of cancer is associated with DNA damage which allows subjects to be stratified for particular therapies including immune therapies which may be combined with DNA damage therapeutics. A method for predicting responsiveness to an antagonist of an inhibitory immune checkpoint and/or an agonist of a stimulatory immune checkpoint comprises determining the expression level of at least one gene selected from Table 2B, 2A or 1 in a sample from the subject. The determined expression level is used to predict responsiveness to an antagonist of an inhibitory immune checkpoint and/or an agonist of a stimulatory immune checkpoint.Type: ApplicationFiled: July 21, 2016Publication date: October 17, 2019Applicant: ALMAC DIAGNOSTICS LIMITEDInventors: Timothy Davison, Jude O'Donnell, Max Bylesjo, Fionnuala Patterson, Steve Deharo, Laura A. Hill, Katherine E. Keating, Vitali Proutski, Denis Paul Harkin, Richard Kennedy, Nicolas Goffard, Steven Walker, Laura Taggart, Eileen Parkes
-
Patent number: 10421191Abstract: A system is provided including a first elongated object proximate a first surface on a first side of a structure and a second elongated object proximate a second surface on a second side of the structure, the second surface and the second side opposite the structure relative to the first surface and the first side, the first object aligned with the second object at a first point on the first surface. The system also includes a first plurality of corner cubes affixed to the first object at first known distances from each other and from the first point, wherein the first object abuts the first surface at the first point. The system also includes a second plurality of corner cubes affixed to the second object at second known distances from each other and from the first point, wherein the second object abuts second surface at second point opposite first point.Type: GrantFiled: April 25, 2017Date of Patent: September 24, 2019Assignee: The Boeing CompanyInventors: John Willard Dorsey-Palmateer, Michael Richard Kennedy
-
Publication number: 20190269949Abstract: A safety system includes (a) a rope or lanyard; (b) a safety hook attached to the rope or lanyard; (c) a load detection sensor retrofit to the hook without altering the structural integrity of the hook; and (d) a transmitter arranged to convey a load status signal.Type: ApplicationFiled: May 20, 2019Publication date: September 5, 2019Inventors: Richard KENNEDY, Alex HOYOS
-
Patent number: 10385480Abstract: Provided are metallic sulfide coated travelers, particularly tungsten disulfide coated travelers, methods of forming metallic sulfide coated travelers, and systems for use of metallic sulfide coated travelers. The metallic sulfide coating results in reduced yarn loading on the coated travelers, reduced heat generation during the spinning operation, and reduced wear of the traveler.Type: GrantFiled: March 10, 2017Date of Patent: August 20, 2019Assignee: AB Carter Inc.Inventors: Richard Kennedy Craig, Fred Pearson Rankin, Behzad Abedi-Asl, Gereon Elmer Poquette, Taylor Ross Hopkins
-
Patent number: 10378066Abstract: Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test defines a novel DNA damage repair deficient molecular subtype and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any chemotherapy. This test may be used in different cancer types and with different drugs that directly or indirectly affect DNA damage or repair, such as many of the standard cytotoxic chemotherapeutic drugs currently in use. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.Type: GrantFiled: February 7, 2017Date of Patent: August 13, 2019Assignee: Almac Diagnostic Services LimitedInventors: Jude O'Donnell, Max Bylesjo, Fionnuala Patterson, Steve Deharo, Laura A. Hill, Katherine E. Keating, Timothy Davison, Vitali Proutski, Denis Paul Harkin, Richard Kennedy, Nicolas Goffard
-
Patent number: 10370196Abstract: A food patty aligning and separating apparatus with a conveyor belt having horizontal cleats extending through a hopper beneath patties. Dividers extend longitudinally through the hopper to form lanes. The conveyor belt's cleats urge patties along lanes up a vertical span of the conveyor, thereby aligning the patties horizontally in a line. The patties pass over a peak and slide down a curved plate to distance the aligned group of patties from a next upstream group of patties. Guide members are spaced from the conveyor belt on hopper side to shear combined patties or pivot outward and cause combined patties to roll back into the hopper.Type: GrantFiled: January 31, 2018Date of Patent: August 6, 2019Assignee: J.E. Grote Co., Inc.Inventors: Clifford E. Fitch, III, Cory Richard Kennedy
-
Patent number: 10280468Abstract: Methods for selecting whether to administer an anti-angiogenic therapeutic agent to a subject include steps of measuring the expression levels of one or more biomarkers selected from Table 2 or Table 3 in a sample from the subject; assessing from the expression levels of the one or more biomarkers whether the sample from the subject is positive or negative for a biomarker signature, wherein if the sample is positive for the biomarker signature an anti-angiogenic therapeutic agent is contraindicated. Related prognostic methods and treatment methods are also provided. The invention is particularly applicable in ovarian and colorectal cancers.Type: GrantFiled: February 9, 2015Date of Patent: May 7, 2019Assignee: Almac Diagnostics LimitedInventors: Denis Paul Harkin, Richard Kennedy, Katherine E. Keating, Andrena McCavigan, Laura A. Hill, Steve Deharo, Timothy Davison, Fionnuala Patterson, Sinead Donegan, Gera Jellema, Charlie Gourley
-
Publication number: 20190127805Abstract: A molecular subgroup of cancer is characterised by misregulation of the MAPK signalling pathway and the epithelial-mesenchymal transition (EMT) pathway. Biomarker signatures can be used to identify cancers within the molecular subgroup. The signatures are also useful for identifying the treatment that is best suited for a given patient. A method for selecting a treatment for a subject having a cancer, comprises measuring the expression level(s) of at least biomarker selected from Table A or Table B in a sample from the subject. By assessing the expression level(s) of the at least 1 biomarker it can be determined whether the sample from the subject is positive or negative for a biomarker signature comprising the at least 1 biomarker. Based on the outcome of this assessment different treatments selected from MAPK pathway 10 inhibitors, EMT pathway inhibitors, SRC pathway inhibitors, taxanes and anti-angiogenic therapeutic agents may be indicated. Related treatment methods and products are also provided.Type: ApplicationFiled: March 13, 2017Publication date: May 2, 2019Applicant: ALMAC DIAGNOSTICS LIMITEDInventors: Aya EL-HELALI, Niamh MCGIVERN, Andrena MCCAVIGAN, Bethanie PRICE, Laura KNIGHT, Nuala MCCABE, Richard KENNEDY, Paul HARKIN, Charlie GOURLEY
-
Patent number: 10260097Abstract: Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test identifies cancer subtypes that are responsive to anti-angiogenesis therapeutics and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any anti-angiogenic agent. This test may be used in different cancer types and with different drugs that directly or indirectly affect angiogenesis or angiogenesis signalling. In addition, the present invention may be used as a prognostic indicator for certain cancer types. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.Type: GrantFiled: June 4, 2012Date of Patent: April 16, 2019Assignee: Almac Diagnostics LimitedInventors: Denis Paul Harkin, Fionnuala Patterson, Claire Trinder, Eamonn J. O'Brien, Caroline Michie, Charlie Gourley, Laura A. Hill, Katherine E. Keating, Jude O'Donnell, Max Bylesjo, Steve Deharo, Vitali Proutski, Richard Kennedy, Timothy Davison, Andreas Winter, Andrena McCavigan
-
Patent number: 10214777Abstract: Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test defines a novel DNA damage repair deficient molecular subtype and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any chemotherapy. This test may be used in different cancer types and with different drugs that directly or indirectly affect DNA damage or repair, such as many of the standard cytotoxic chemotherapeutic drugs currently in use. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.Type: GrantFiled: August 13, 2015Date of Patent: February 26, 2019Assignee: Almac Diagnostics LimitedInventors: Jude O'Donnell, Max Bylesjo, Fionnuala Patterson, Steve Deharo, Laura A. Hill, Katherine E. Keating, Timothy Davison, Vitali Proutski, Denis Paul Harkin, Richard Kennedy, Nicolas Goffard
-
Patent number: 10196697Abstract: A method is provided for characterizing and/or prognosing prostate cancer in a subject comprising determining the expression level of at least one of CREM, ERRFI1, SRSF5, PDK4, HJURP, PDRG1, TRPM3, PDE4D, FI2, ADAMTS1, ADAMTS9, B3GNT5, CD38, CEBPD, CENPF, DKK1, EMP1, F3, IL1R1, IL8, JUNB, KLFIO, KLF4, LDLR, LGALS3, LPARI, MALAT1, MTUS1, MYBPC1, NFIL3, NR4A3, OAT, PI15, PTGS2, RHOBTB3, RIN2, RNFT2, SELE, SLC15A2, SOCS2, SOCS3, SSTR1, ST6GAL1, TSC22D1, XBP1 and ZFP36 in a sample from the subject. The method may be used to predict the likelihood of metastasis. Also disclosed are methods for diagnosing and selecting treatment for prostate cancer, together with corresponding methods of treatment. Systems, kits and computer programs for performing the methods are also provided.Type: GrantFiled: December 12, 2014Date of Patent: February 5, 2019Assignee: ALMAC DIAGNOSTICS LIMITEDInventors: Steven Walker, Andrena McCavigan, Timothy Davison, Richard Kennedy, Paul Harkin, Laura Hill